Adaptimmune Therapeutics plc (ADAP)

Market Cap	169.99M
Revenue (ttm)	175.04M
Net Income (ttm)	-44.52M
Shares Out	255.75M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,158,652
Open	0.680
Previous Close	0.675
Day's Range	0.640 - 0.705
52-Week Range	0.421 - 2.050
Beta	2.25
Analysts	Strong Buy
Price Target	3.16 (+375.4%)
Earnings Date	Nov 13, 2024

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreemen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2015
• Employees: 449
• Stock Exchange: NASDAQ
• Ticker Symbol: ADAP
• Website: https://www.adaptimmune.com

Financial Performance

In 2023, Adaptimmune Therapeutics's revenue was $60.28 million, an increase of 122.05% compared to the previous year's $27.15 million. Losses were -$113.87 million, -31.18% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ADAP stock is "Strong Buy." The 12-month stock price forecast is $3.16, which is an increase of 375.40% from the latest price.

Price Target

$3.16

(375.40% upside)

Analyst Consensus: Strong Buy